This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hanania, N. Articles by Harel, J. Search for Related Content PubMed PubMed Citation Articles by Hanania, N. Articles by Harel, J.

Effects of Tumor Promoters on the Expression of a Tumor-related Multigenic Set in Human Cells¹

Groupe de Recherche de Cancérologie Expérimentale Institut Gustave-Roussy and GR 8 du C.N.R.S.-BP 8 94 800 Villejuif [N. H., D. S., D. Z., J. H.], and Institut de Recherches Scientifiques sur le Cancer-Centre National de la Recherche Scientifique, Villejuif [M. C.], France

We previously found that a minor subfraction of the human genomic DNA, corresponding to 2500–3000 nonrepetitive sequences of 3 kilobases each and designated as tumor-activated DNA (TaDNA) was transcriptionally active in Burkitt's lymphoma cells and almost inactive in normal lymphocytes growing in vitro following integration of the Epstein-Barr virus genome. Furthermore all the neoplastic cells in culture or primary neoplasms (leukemias, sarcomas, carcinomas) studied contained transcripts from most of the TaDNA sequences found in malignant lymphoblasts whereas normal cells growing in vitro contained only a few TaDNA transcripts. It is shown in the present study that treatments of the myeloid leukemia HL60 cells with various inducers of cell differentiation (dimethyl sulfoxide, retinoic acid, mezerein, 12-O-tetradecanoylphorbol-13-acetate, teleocidin) caused a dose-dependant reduction of the level of TaDNA transcripts, correlated with the diminution of c-myc transcripts.

The 12-O-tetradecanoylphorbol-13-acetate treatment had this same effect on Burkitt's lymphoma cells (Raji or Namalwa) but the opposite effect on normal cells (Epstein-Barr virus-immortalized lymphocytes or fetal fibroblasts) where it enhanced the formation of Ta-DNA transcripts up to the levels found in untreated malignant cells. These data suggest two conclusions (a) TaDNA corresponds to a multigenic set which seems to be involved in modulation of the malignant phenotype and (b) depending on the origin of the cells, agents like 12-O-tetradecanoylphorbol-13-acetate may operate either as tumor promoters or as differentiation inducers through the control of TaDNA expression.

¹ This work was carried out with the financial support of Association pour la Recherche sur le Cancer and Fonds pour la Recherche Clinique of Institut Gustave-Roussy.

² To whom requests for reprints should be addressed.

Received 1/28/85. Revised 7/17/85. Accepted 8/28/85.